ALVR106 in Treatment of High-Risk Patients with Respiratory Viral Infections After HSCT or SOT
What is the Purpose of this Study?
- Be randomly assigned (like a coin flip) to get either the study drug or placebo (inactive substance)
- Have physical exams
- Have blood draws
- Have breathing tests
- Get a chest X-Ray or CT scan
- Have heart scans (ECG)
Depending on when you join the study, you will participate in Part A or Part B. In Part A, 4 different doses of the study drug will be tested. In Part B, only the most effective dose determined by Part A will be used.
Your participation in this study will last for about 1 year.
Who Can Participate in this Study?
Adults ages 18-75 who:
- Have a viral infection of the lungs (contact study team for eligible viral infections)
- Received a bone marrow transplant in the past 21 days
- Have not had a suspected COVID-19 infection in the last 28 days
For more information about who can join this study, please contact the study team at firstname.lastname@example.org.
What is Involved?
We are doing this study to find out if an experimental drug called ALVR106 (study drug) is a safe and effective treatment for people who have viral lung infections after receiving a bone marrow transplant. We also want to determine what dose level of the drug works best.